Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration

Table 2

Baseline characteristics of early versus delayed 15-letter responders.

	Fixed monthly dosing				Less frequent dosing
	ANCHOR		MARINA		PIER		SAILOR cohort 1 treatment-naïve at Baseline
	Early 15-letter	Delayed 15-letter	Early 15-letter	Delayed 15-letter	Early 15-letter	Delayed 15-letter	Early 15-letter	Delayed 15-letter
	responders	responders	responders	responders	responders	responders	responders	responders
	(n = 82)	(n = 41)	(n = 87)	(n = 77)	(n = 18)	(n = 6)	(n = 187)	(n = 57)
Demographics
Gender, % female	46	54	63	66	39	50	56	51
Age, mean years	76	75	77	76	78	80	78	79
VA, mean letters	43*	51	47*	53	46	49	49	52
Prior therapy for AMD,^a %	17	17	9	5	22	0	0	0
Total area of, mean DA
Lesion	1.7	1.6	4.0	4.2	4.1	1.7	NA	NA
CNV	1.3	1.2	3.8	4.1	3.4	1.5	NA	NA
Classic CNV	1.1	1.1	0.2	0.2	0.7	0.1	NA	NA
Classic CNV, % of lesion area	65	69	5	4	32	14	NA	NA
Leakage + RPE staining	2.8	2.5	3.1	3.4	3.8	2.2	NA	NA

^∗𝑃<0.05 comparing early 15-letter responders versus delayed 15-letter responders.
AMD: age-related macular degeneration; CNV: choroidal neovascularization; DA: optic disk areas; NA: not available; RPE: retinal pigment epithelium; VA: visual acuity.
^aPrior therapies for AMD included extrafoveal photodynamic therapy, laser photocoagulation (juxtafoveal or extrafoveal photocoagulation was allowed 1 month or more preceding day 0 in ANCHOR, MARINA, and PIER), and injections of triamcinolone acetonide and alteplase injection (intravitreal) to displace blood. Note: some study-eye prior therapies were excluded in the ANCHOR, MARINA, PIER, and SAILOR clinical trial protocols.